MONTREAL, QUEBEC--(CCNMatthews - April 13, 2007) - Thallion Pharmaceuticals Inc. (TSX:TLN) today provided an update on its participation in a joint advisory panel convened by the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research. Thallion, as a sponsor participant, presented to the joint committee on questions posed by the FDA, on subjects including the suitable endpoints for products seeking approval for the treatment of Shiga Toxin-producing Escherichia coli infection (STEC). The joint committee considered, among several issues related to therapeutic development in STEC, alternatives to standard endpoints historically used, including those proposed by Thallion to the FDA.
